Obesity drug supply-demand imbalance is working in Novo Nordisk’s favor: Mizuho’s Jared Holz

Jared Holz, Mizuho Securities, joins ‘Fast Money’ to talk demand in the obesity drug space and who is benefiting from the supply-demand imbalance.